Chemomab Therapeutics Ltd. (CMMB:NASDAQ) closed at $1.05 on October 27, 2026, up 5.00% on the day. The stock trades 68.1% below its 52-week high of $3.29 and 14.1% above its 52-week low of $0.920. Over the past year, it lost 67.2%. Chemomab Therapeutics Ltd. is part of the Health Care sector.
In 252 trading sessions since October 24, 2025, CMMB closed higher on 108 days (43%). Its best day was July 2, 2026 (+33.53%) and its worst was July 8, 2026 (-28.88%). The stock moved 10% or more in a single session 14 times. It opened at least 5% above the previous day's high 1 time.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Find more stocks like CMMB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.